Clinical Trial Update: ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis" [Phase 2]

View source ↗

Summary

This update covers a Phase 2 trial evaluating the best loading dose of clopidogrel to blunt platelet activation, inflammation, and ongoing necrosis in ischemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ischemia

Drugs mentioned

• CLOPIDOGREL (CLOPIDOGREL)

Snippet

Sponsor: Sanofi | Conditions: Ischemia | Phase 2 | Status: COMPLETED